Top stocks to buy: Stock recommendations for the week starting July 7, 2025
Stock market recommendations:
According to Motilal Oswal Financial Services Ltd, the top stock picks for the week (starting July 7, 2025) are INOX Wind, and Coforge. Let's take a look:
Name
CMP
Target
Upside
INOX Wind
180
210
17%
Coforge
1946
2200
13%
INOX Wind
INOX Wind Ltd (IWL), a leading integrated wind OEM in India, offers end-to-end solutions from turbine manufacturing to project execution & O&M.
Backed by 2.5GW capacity & a robust 3.2GW order book, it is well-positioned to benefit from India's plan to double its wind capacity to 100GW by 2030.
Wind Turbine Generators (WTG) ramp-up & O&M scale-up are underway, supported by a 1,500MW turnkey order & growing repeat business. Its subsidiaries IGESL (O&M, 5.1GW portfolio) & IRSL (EPC, now diversifying into solar/hybrid/crane services) enhance group synergies.
Backed by policy tailwinds & a new 4MW turbine pipeline, we estimate 48% revenue & 38% EBITDA CAGR over FY25–28. Strong visibility, clean balance sheet, & execution momentum support a long-term structural growth story.
Coforge
We reiterate our BUY on Coforge, supported by a robust executable order book of USD 1.5b (+47% YoY) and strong traction in BFSI and transportation, both growing over 20% YoY in FY25. The company is on track to achieve its USD 2b revenue target by FY27, aided by organic growth, Cigniti-led cross-sell, and the landmark USD 1.6b Sabre deal.
by Taboola
by Taboola
Sponsored Links
Sponsored Links
Promoted Links
Promoted Links
You May Like
Free P2,000 GCash eGift
UnionBank Credit Card
Apply Now
Undo
Cross-currency gains and broad-based client momentum across BFSI and Insurance (~48.5% of revenue) further enhance visibility. Margins are set to expand, with one-offs behind and tailwinds from delivery mix and lower ESOP costs; management is targeting 18% EBITDA margin by FY27. Margin improvement is already visible, with EBIT margin rising to 14% in 1QFY26.
Stay informed with the latest
business
news, updates on
bank holidays
and
public holidays
.
AI Masterclass for Students. Upskill Young Ones Today!– Join Now
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mint
8 minutes ago
- Mint
Samsung share price dips: Earnings miss to Trump tariffs — key reasons behind the fall explained
Samsung share price: Samsung Electronics' share price declined in trade on Tuesday after the company delivered an earnings shock, projecting a 56% drop in its second-quarter operating profit, dented by US curbs on China and delays in supplying high-bandwidth memory (HBM) chips to key US customer Nvidia. Additionally, US President Donald Trump levied a 25% tariff on South Korea, further clouding the outlook for the stock. Samsung, one of the world's largest makers of memory chips, reported a preliminary operating profit of 4.6 trillion won in the June quarter — the company's lowest since 2023 and short of analysts' projections, as per a Bloomberg report. The revenue was flat at 74 trillion won. The company will provide a full financial statement with net income and divisional breakdowns later this month. Samsung reported a drop in profit after its foundry division, partly dependent on Chinese demand, incurred a one-time inventory charge for unsold AI chips. The company also noted a decline in utilisation rates, explaining the weaker-than-expected performance in an unusual statement. However, Samsung expects operating losses in its contract chipmaking business to narrow in the second half of the year, citing a gradual recovery in demand. Samsung lost its leadership in the AI market to rival SK Hynix Inc. Its longstanding rival — along with Micron Technology Inc. — now sells more of the cutting-edge high-bandwidth memory chips paired with Nvidia Corp.'s AI accelerators, the Bloomberg report said. What's worse, the problem for Samsung has been compounded by the US restrictions on tech exports to China, thus slowing a turnaround in its chipmaking operation. "Samsung's operating profit dropped by a sharper-than-expected 56% due to inventory write-downs triggered by US export restrictions on AI chips destined for China. Trump's tariff policy had a significant impact on the company's performance," said capital market expert Anuj Gupta. He said that given growing macroeconomic uncertainties due to recent global trade tensions and slowing global economic growth, it is difficult to predict future performance. Due to the festival season in India, we expect its performance to improve in the second half of the year and expect an increase in demand growth, Gupta added. Samsung share price declined over 1% to 61,000 KRW from its last closing price of 61,700 KRW. "Last year, prices corrected by 32.23%. Currently, it has strong resistance at 65000krw and support at 57300krw. We are expecting the price to go down. Traders can use buy-on dips as prices are traded in an oversold zone," Gupta advised. Meanwhile, Anshul Jain, Head of Research at Lakshmishree Investments said that Samsung Electronics' share price has been trading in a wide 240-week range between 85,000 and 49,000 South Korean Won (KRW), recently rejecting the lower end of this range and forming a promising double bottom setup. This, he said, signals a potential preemptive reversal with a solid base. "A sustained move above 62,000 KRW per share will likely propel the stock towards 71,000 KRW apiece, and if momentum persists, a test of 85,000 KRW per share could be in sight. The substantial accumulation at the range lows suggests buyers are defending this zone aggressively. Only a close below 48,000 KRW per share can damage this structure, which currently looks unlikely given the price," Jain opined. (With inputs from agencies) Disclaimer: This story is for educational purposes only. The views and recommendations made above are those of individual analysts or broking companies, and not of Mint. We advise investors to check with certified experts before making any investment decisions.
Time of India
19 minutes ago
- Time of India
Samsung to buy US healthcare services company Xealth
Samsung Electronics said on Tuesday it had signed an agreement to acquire Xealth, a U.S.-based healthcare platform, as part of its efforts to expand its mobile healthcare services business. The South Korean company did not disclose the value of the transaction. Samsung said the two companies hoped to create "synergy between Samsung's advanced wearable technology and Xealth's digital health platform " which runs digital health programs and manages data linking care providers, including more than 500 U.S. hospitals, with their patients. The acquisition comes as Samsung steps up efforts to diversify beyond its core semiconductor and smartphone businesses. Samsung has been betting on the medical sector as one of its new growth engines, along with consumer audio, cooling and heating systems, and robotics. In May, Samsung Electronics agreed to buy Germany's FlaktGroup for 1.5 billion euros ($1.68 billion) as it looks to meet growing demand for cooling of data centres used for artificial intelligence projects. Live Events Samsung, led by Chairman Jay Y. Lee, said at a shareholder meeting in March that it was looking for "meaningful" deals this year to drive growth after having lagged rivals in tapping the AI chip boom led by Nvidia. Samsung earlier on Tuesday projected a far worse-than- expected 56% plunge in second-quarter operating profit due to weak AI chip sales, deepening investor concerns over the tech giant's ability to revive its struggling semiconductor business .
News18
an hour ago
- News18
NITI Aayog Calls For Quality Overhaul In Pharma, Industry Flags Challenges
Last Updated: Concerns raised included the increasing number of Not of Standard Quality drug alerts, workforce issues and unsustainable drug pricing policies In a high-level consultation led by NITI Aayog on Monday, leading pharmaceutical industry bodies raised pressing concerns over drug quality, regulatory enforcement, and systemic gaps in technical manpower and infrastructure. The meeting, chaired by Dr VK Paul (Member, Health), was aimed at aligning India's pharmaceutical standards with global benchmarks. Held at NITI Aayog headquarters, the central focus was to assess the challenges hampering the production of high-quality, globally acceptable pharmaceutical products, and to chart a strategy for reform. The Niti Aayog, in its invite, mentioned that it aims to discuss the challenges in producing high-quality medicines while also upholding the title of pharmacy to the world. 'A rigorous focus on quality is also essential to ensure patient safety and trust in public health in the domestic market. With a strong network of over 3,000 pharmaceutical companies and approximately 10,500 manufacturing units across the country, it is essential to invest in and uphold the highest quality standards for pharmaceuticals," highlighted the letter sent to various industry associations, including Indian Pharmaceutical Alliance (IPA), Indian Drug Manufacturers' Association (IDMA), Laghu Udyog Bharati, Bulk Drug Manufacturers Association (India), Organisation of Pharmaceutical Producers of India (OPPI), Federation of Pharma Entrepreneurs (FOPE) among others. Industry Flags NSQ and Workforce Issues One of the dominant concerns raised was the increasing number of Not of Standard Quality (NSQ) drug alerts. Industry representatives pointed to poor educational standards in pharmacy colleges, which, they said, result in technically under-qualified personnel who are unable to handle the drug inspectors coming for audit. 'The industry highlighted that the gap in technical competence is directly impacting manufacturing quality," an industry official told News18, requesting anonymity. Representatives from the Confederation of Indian Pharmaceutical Industry (CIPI) highlighted the structural and financial constraints faced by MSMEs, especially in conducting stability studies, a critical requirement for ensuring drug quality. They urged the government to provide financial support for MSMEs to build necessary infrastructure, arguing that this could significantly reduce NSQ cases. The industry also advocated for exclusive engagement meetings between policymakers and MSME associations to address deep-rooted, sector-specific issues that are often overlooked in broader policy discussions. In a strong counter-point, RSS-led Laghu Udyog Bharati challenged the narrative that MSMEs are primarily responsible for quality failures. 'US FDA failure by large corporations is generally overlooked in India and small deviations by micro, small and medium enterprises (MSMEs) are given more attention. This has created a bad image of the MSME industry. Big pharma companies are facing product recalls on a regular basis but no one talks about them," Dr Rajesh Gupta, who represents Laghu Udyog Bharati and supports MSME industry, said. 'The myth of 'Brand Bharat' created by large corporations ignores the fact that MSMEs manufacture and sell 97.3 per cent of India's drugs. Yet, only 2.64 per cent are NSQ-declared, and often with no reported harm to patients," Gupta told Newa18, mentioning that he presented the same argument before the government officials in the meeting. Drug Pricing Pressures: Quality vs Affordability Concerns were also raised around the unsustainable drug pricing policies of the price watchdog, National Pharmaceutical Pricing Authority. Industry participants cautioned the government that low price ceilings have made it unviable for manufacturers to produce quality formulations. As an example, they cited cotrimoxazole, an essential antibiotic, which has reportedly vanished from the domestic market due to pricing stress. 'Government wants us to upgrade quality standards and we will do that. But that comes at a cost. We are investing in technology as well as a skilled workforce. While investments are increasing, we are not allowed to increase prices of products. Hence, we are being pushed to discontinue products," said an industry official part of the meeting. Regulator's Firm Stand on GMP and Accountability Drug Controller General of India Dr Rajeev Singh Raghuvanshi, as per industry sources who were part of the meeting, gave a clear message to the industry, saying: 'There will be no relaxation in enforcement of GMP (Good Manufacturing Practices)." 'Emphasising accountability, he outlined a stricter protocol for handling NSQ cases—companies would now face license suspension after a two-week show-cause notice—with reinstatement only upon satisfactory Corrective and Preventive Action (CAPA) review," said the official quoted above. 'He also expressed disappointment with the role of pharma manufacturing associations, urging them to take more responsibility in ensuring that member units uphold quality norms." top videos View all In the ongoing debate between Indian Pharmacopoeia (IP) and WHO-GMP, the DCGI clarified that the two should be seen as parallel and non-conflicting systems. Overall, Gupta and other industry representatives who attended the meeting told News18 that senior government officials, including DCGI and Dr Paul listened attentively to their concerns. The officials were described as patient and receptive, urging the industry to submit their queries in writing for further consideration. 'Everyone was considerate and gave us ample time to present our concerns," Gupta from LBU said. tags : niti aayog pharma sector VK Paul Location : New Delhi, India, India First Published: July 08, 2025, 10:06 IST News india NITI Aayog Calls For Quality Overhaul In Pharma, Industry Flags Challenges
